Welcome to our dedicated page for Tiziana Life Sciences Com news (Ticker: TLSA), a resource for investors and traders seeking the latest updates and insights on Tiziana Life Sciences Com stock.
Tiziana Life Sciences Ltd. (NASDAQ: TLSA) is a clinical-stage biopharmaceutical company whose news flow centers on the development of intranasal foralumab, a fully human anti-CD3 monoclonal antibody, and related immunomodulation programs. Company announcements highlight progress in neuroinflammatory and neurodegenerative indications, including non-active secondary progressive multiple sclerosis, early Alzheimer’s disease, and amyotrophic lateral sclerosis (ALS).
News about Tiziana often covers key clinical milestones. Recent releases describe dosing of patients in a Phase 2 randomized, placebo-controlled trial of intranasal foralumab in early Alzheimer’s disease, including evaluation as monotherapy and in combination with FDA-approved anti-amyloid therapies lecanemab and donanemab. Other updates report on the Expanded Access Program in non-active secondary progressive multiple sclerosis and the acceptance of the company’s ALS Phase 2 trial into the ALS MyMatch Program at the Sean M. Healey & AMG Center for ALS.
Investors following TLSA news can also expect regulatory and safety updates, such as the submission of Development Safety Update Reports to the U.S. Food and Drug Administration, which summarize cumulative exposure and safety findings for intranasal foralumab. Corporate and capital markets news includes insider share purchases by senior leadership, decisions regarding proposed public offerings, and participation in industry conferences like BIO-Europe, the Jefferies London Healthcare Conference, and neuroscience-focused forums.
This news page aggregates these company-issued press releases and related coverage, giving readers a centralized view of Tiziana’s clinical progress, regulatory interactions, strategic initiatives such as the planned spinout of IL-6 asset TZLS-501, and visibility events like ringing the Nasdaq Closing Bell. Users interested in TLSA can review this feed to monitor how Tiziana’s immunotherapy and drug delivery programs evolve over time.
Tiziana Life Sciences (Nasdaq: TLSA) announced that research published in Frontiers in Immunology supports its intranasal foralumab as a promising treatment for autoimmune and CNS diseases. Conducted by Brigham and Women's Hospital and Harvard Medical School, the study involving 27 volunteers demonstrated a favorable safety profile with no adverse events across doses of 10ug, 50ug, and 250ug. Notably, immunological effects peaked at the 50ug dosage, showing potential for future clinical applications without the side effects common in IV anti-CD3 treatments.
Tiziana Life Sciences Ltd. (Nasdaq: TLSA) announced a corporate update focusing on the development of intranasal foralumab for CNS inflammatory diseases. The company aims to prioritize resources for this therapeutic candidate, leveraging positive preclinical results. Upcoming milestones include results from PET scans for patients with non-active secondary-progressive Multiple Sclerosis expected in Q1 2023, and plans for an FDA Type C meeting regarding its Phase 2 program. Tiziana has sufficient capital to fund developments until Q1 2024.
Tiziana Life Sciences Ltd. (Nasdaq: TLSA), a clinical-stage biotechnology company, announced an investor call and webcast scheduled for November 10, 2022, at 10 a.m. ET. This session will provide insights into their innovative immunomodulation therapies utilizing novel drug delivery methods. Tiziana's leading candidates include intranasal foralumab and milciclib, both showing promising safety profiles and clinical responses. The company focuses on alternative routes for immunotherapy, aiming to enhance efficacy and safety compared to traditional IV delivery.
Tiziana Life Sciences Ltd. (Nasdaq: TLSA) announced that Panetta Partners Limited, associated with Executive Chairman Gabriele Cerrone, purchased 7,000 common shares at $0.69 each. With this transaction, Cerrone's overall interest in Tiziana remains significant at 37.70%. Tiziana focuses on innovative drug delivery technologies for immunotherapies, including its lead candidates: intranasal foralumab, the only fully human anti-CD3 mAb, and milciclib, a pan-CDK inhibitor. These candidates are showing favorable safety profiles and responses in clinical studies.
Tiziana Life Sciences (Nasdaq: TLSA) has completed enrollment of the first patient cohort (n=4) in its Expanded Access Program for foralumab, a treatment for non-active Secondary Progressive Multiple Sclerosis (SPMS). Conducted at Brigham and Women’s Hospital, the program assesses two dosing levels: 50 mcg and 100 mcg. This initiative follows positive feedback from investigators and aims to validate the clinical benefits of foralumab, with results from initial PET scans expected soon, potentially paving the way for Phase 2 studies in the coming year.
Tiziana Life Sciences Ltd. (Nasdaq: TLSA) announced the enrollment of its first patient cohort in an Expanded Access Program to evaluate foralumab in non-active Secondary Progressive Multiple Sclerosis (SPMS) patients. This program includes two cohorts of four patients each, testing standard and higher dosing of foralumab. Conducted at Brigham and Women’s Hospital, the study aims to assess the clinical benefits of intranasal foralumab, with PET scans for initial patients scheduled in the coming months, supporting a Phase 2 study expected to begin in mid-to-late 2023.
Tiziana Life Sciences Ltd (NASDAQ: TLSA) will participate in The ThinkEquity Conference on October 26, 2022, at The Mandarin Oriental Hotel, New York. Dr. Matthew W. Davis will present at 2:30 p.m. ET, with live streaming available. Tiziana is focused on innovative immunomodulation therapies through alternative drug delivery methods like nasal and oral routes. Their leading candidates, intranasal foralumab and milciclib, have shown favorable clinical responses. This conference will connect industry insiders and investors, featuring presentations and discussions across various sectors.
Tiziana Life Sciences (Nasdaq: TLSA) announced plans to submit an Investigational New Drug Application (IND) for a Phase 1 trial of intranasal foralumab targeting Alzheimer's disease after receiving feedback from the FDA. The IND is expected to be filed in Q3 2023, pending toxicology study completions, with the trial commencing by year-end. Foralumab, a fully human anti-CD3 monoclonal antibody, has shown promise in treating CNS-related inflammatory diseases. The company aims to explore its efficacy in other conditions such as Multiple Sclerosis and Amyotrophic Lateral Sclerosis.
Tiziana Life Sciences (Nasdaq: TLSA) presented poster exhibits on intranasal foralumab for treating Progressive Multiple Sclerosis (MS) at the "Preserving the Brain" conference in Milan, Italy. The presentation included results from animal models, healthy subjects, and patients with Progressive MS. Dr. Howard L. Weiner interviewed the first patient treated with intranasal foralumab during the event. Gabriele Cerrone, Executive Chairman, expressed excitement over the recognition of this therapy. The conference aims to advance discussions on neurodegenerative diseases and will run until October 10, 2022.
Tiziana Life Sciences Ltd. (Nasdaq: TLSA) announced positive developments regarding its intranasal foralumab treatment for non-active secondary progressive multiple sclerosis (SPMS). The second Expanded Access patient (EA2) exhibited improved walking ability, requiring no cane for 100 meters, and showed a clinically significant 0.5 point decrease on the Expanded Disability Status Scale (EDSS). These results will be further evaluated with PET imaging to assess microglial activation in Q4 2022. The company plans to enroll four additional patients at Brigham and Women’s Hospital during the same period.